Deirdre Geraghty is a partner in A&L Goodbody's Corporate and M&A group and is based in the New York office. She has extensive experience advising international and domestic clients on all aspects of corporate law including public and private M&A, equity capital markets, corporate restructurings and corporate governance. Deirdre advises clients across a range of industry sectors including pharma/healthcare, technology and energy. She also frequently advises US companies who are establishing operations in Ireland for the first time, having spent a number of years in A&L Goodbody's New York office.
Areas of Expertise
Corporate and M&A/Capital Markets – Equity/PLC Advisory & Governance/Investing in Ireland/Corporate Advisory & Company Law/Corporate migrations to Ireland and de-SPAC M&A
Experience Advising:
- ESB on its strategic renewable energy joint venture with Coillte, FuturEnergy Ireland
- IPS-Integrated Project Services, a portfolio company of Alleghany Capital, on its acquisition of Linesight
- Iterum Therapeutics plc on its $52m convertible debt financing
- Morgan Stanley, as AbbVie Inc’s lead financial advisor and lender, in connection with AbbVie’s $63bn acquisition of Allergan plc
- Osmotica Pharmaceuticals plc on its IPO on NASDAQ
- Iterum Therapeutics plc on its IPO on NASDAQ
- Adient plc on its $5bn spin-off from Johnson Controls plc
- Johnson Controls Inc. on its $20bn merger with Tyco plc
- Medtronic, Inc. on its $49bn acquisition of Covidien plc in January 2015 (Global M&A Deal of the Year 2015: Ireland - American Lawyer)
Education
- Solicitor, Law Society of Ireland
- MSc in the Business of Law, UCD Smurfit Graduate Business School
- BBLS, University College Dublin
Deirdre Geraghty
Partner, Corporate and M&A
New York